ArticleMetabolic brain disease2025
Ranolazine neuroprotection against middle cerebral artery occlusion/reperfusion ischemic injury via modulation of brain-derived neurotrophic factor and brain mitochondrial tu translation elongation factor (TUFM).
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effects of Different Doses of Ranolazine on SIRT1, APELA, and APL13 in a Rat MCAO Model.Current issues in molecular biology · 2026Article
- Exercise Improves Mitochondrial Homeostasis: A Potential Neuroprotective Strategy for Ischemic Stroke.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study investigates the therapeutic potential of Ranolazine in cerebral ischemic stroke, focusing on its neuroprotective properties in a middle cerebral artery occlusion/reperfusion (MCAO/R) induced ischemic brain injury in a rat model. Ranolazine demonstrated neuroprotective effects by reducing infarct size and brain edema, improving cerebral blood flow, and preserving blood-brain barrier integrity, leading to improved neurological function. Mechanistically, ranolazine decreased HIF-1α and GFAP expression while enhancing BDNF levels. Ranolazine increased mitochondrial complex enzyme activities (I, II, IV, and V) and enhanced the expression of the mitochondrial Tu translation elongation factor (TUFM), NRF1, and PGC-1α levels, indicating improved mitochondrial biogenesis and decreased mitochondrial oxidative stress markers such as 4-HNE and increased catalase and SOD. Further, ranolazine treatment reduced the levels of pro-inflammatory cytokines TNF-α and IL-6 while increasing the anti-inflammatory cytokine IL-10, suggesting its anti-inflammatory potential in mitigating the stroke-associated neuroinflammation. Moreover, ranolazine suppressed apoptosis by reducing the levels of apoptotic mediators such as cytochrome c, caspase-9, and caspase-3, and flow cytometry analysis revealed a significant decline in neuronal apoptosis, which further underscores its neuroprotective efficacy. Therefore, the novelty of this research lies in demonstrating that ranolazine exerts neuroprotective effects against ischemic brain injury by simultaneously modulating apoptotic pathways, restoring vital neurological factors (BDNF, TUFM, NRF-1, PGC-1α), improving mitochondrial function, reducing oxidative stress, and attenuating neuroinflammation, offering a novel multi-targeted therapeutic approach, meriting further clinical studies.
Indexed as
Identifiers
41071439What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.